At equivalent oral doses, cefadroxil has a longer serum half-life, slower urinary excretion rate, greater area under the serum level versus time curve than cephatexin or cephadrine, and peak serum concentrations that are 75 to 80% those of cephalexin. The calculated, apparent in vivo volume of distribution of cefadroxil is greater than that of cephalexin. These properties infer greater persistence of cefadroxil in serum und urine and more prolonged in vivo bacterial exposure to cefadroxil than to cephalexin or cephradine. Neither cefadroxil nor cephalexin demonstrates drug accumulation on repeated administration. The serum levels achieved by cefadroxil are unaffected by food. The pharmacokinetic properties of cefadroxil are supportive of the development of clinical efficacy data which could indicate that cefadroxil could be administered at 12-h-intervals.
Introduction
The studies reported here were undertaken to compare the pharmacokinetic properties in humans of the orally administered cephalosporin antibiotics cefadroxil, cephalexin, and cephradine (structures presented in Fig. 1 ) and to determine the factors which control their disposition in vivo. A companion paper presents data on the antibacterial activity of cefadroxil (1). The inhibitory activity of cefadroxil on clinical isolates was similar to that of cephalexin and cephradine. Cefadroxil was more effective than cephalexin against Streptococcus pyogenes and comparably as effective as cephalexin against Streptococcus pneumoniae, Staphylococcus aureus, and several gramnegative species in oral treatment of experimental infections in mice.
Materials and Methods
Bioassays for antibiotic activity in serum and urine were carried out by standard cup plate assay methodology (4) using Sarcina lutea ATCC 9341 as the bioassay organism versus analytical standards of each of the cephalosporin antibiotics employed. All antibiotic doses administered are reported in terms of antibiotic content as established by bioassay.
In all three studies all subjects gave informed consent to their participation. All subjects were between the ages of 23 and 59 years and weighed between 51 and 83 kg. Additional criteria for entrance into the studies included lack of l~enicillin allergy or sensitivity, a normal routine physical examination, and determinations of hemoglobin, hematocrit, white blood cell and differential count, blood urea nitrogen, serum glutamic pyruvic transaminase, bilirubin, urinalysis (including protein test, sugar and microscopy for casts and cells), and stool parasitological examination, Subjects with abnormal values of findings were not admitted into these studies. None of the subjects were to have taken any medication for 3 weeks prior to the study in which they participated. All subjects were fasted overnight before each study. Oral doses of drugs were always administered at 8:00 a. m. with 250 ml of water, and a further 250 ml of water was ingested every succeeding 2 h for the duration of the study. Except for portions of a study on the effect of food on drug bioavailability, the subjects maintained their fast for 2 h after drug administration. All studies were designed as balanced, randomized complete crossovers. There was a 6-day washout period between crossover legs. Study HL-74-41. The first study was a three-period crossover pharmacokinetic and bioavailability comparison between cephalexin and the monohydrate and trihydrate of cefadroxil. The drugs administered were: cefadroxil monohydrate capsules, 300 mg; cefadroxil trihydrate capsules, 300 mg; and commercial cephalexin monohydrate capsules, 250 mg. There were 16 volunteers (13 males, 3 females). Blood samples for the preparation of serum were taken at zero time (before dosage) and at 0.5, 1, 1.5, 3, 6, and 8 h after dosing. Total urine collections were made during the 0-to-4-and 4-to 8- 500 mg. There were 12 volunteers (11 males and 1 female). Blood samples were collected at zero time and at 0.5, 1, 1.5, 2, 4, 6, 8, and 12 h after dosing. Total urine collections were made over the 0-to 3-, 3-6-, and 6-to 12-h intervals after dosing.
Study HL-75-51. Study HL-75:51 was a four-period crossover comparison directed toward the effect of food on the bioavailabilities of cephalexin monohydrate and cefadroxil monohydrate. Cefadroxil monohydrate capsules, 500 rag, and commercial cephalexin monohydrate capsules, 500 mg, were administered. Sixteen volunteers (10 male and 6 female) were employed. Each volunteer received three consecutive doses of each drug with and without food. There were 24-h intervals between the successive doses. All volunteers took both cefadroxil and cephalexin with and without food. On the test days when drug was administered with food, the volunteers ingested 50 g of bacon, one fried egg, one slice of bread, and one cup of coffee with the drug. On test day 1, blood samples were taken at zero time and at 0.5, 1, 1.5, 3, 6 and 8 h after dosing. On test days 2 and 3, blood samples were taken at 2 and 8 h after dosing. The 8-h blood collections were omitted when the test drug was cephalexin. Total urine collections were made over the 0-to 4-and 4-to 8-h intervals after dosing. into the systemic circulation occurs by passive diffusion (7). A1 and Bx are coefficients; Ka is a first-order rate constant for drug absorption and Ket is a rate constant for drug elimination by first-order processes. The fitting was performed via nonlinear regression analysis using the digital computer program NLIN which employs Marquardt's algorithm (5).
Pharmacokinetic bioavailability and statistical analyses.
The lag time between drug administration and the onset of. absorption, to, was found by setting equation 1 equal to zero and rearranging it:
The time at which peak serum level occurs, tmax, was calculated by setting the differential of equation 1 equal to zero and solving for tmax:
Cm.x, the peak serum level, was calculated by substituting tma x into equation 1. The area under the serum concentration versus time curve (AUC) from t = 0 to infinity was calculated by integrating equation 1 between these time limits:
The renal clearances (Clr) of the drugs were found by plotting the renal excretion rates of the drug (AMu/At) versus serum concentrations at the midpoint times of the urine collection intervals (9) . The total amount of drug in milligrams, Mu, excreted in any given time interval in hours, tl to t2, was divided by the length of the interval to get the renal excretion rate in milligrams per hour:
a n d r":
This was plotted versus serum concentration at time (h + t2)/2. If the serum concentration at a given time had not been experimentally determined, it was estimated by interpolation from a semilogarithmic plot of serum concentration versus time data. This paper reports the mean results by drug and subject groups rather than the results for each subject. In these three studies there were 44 subjects and 12 different treatments for a total of 528 sets of serum-urine data. The goodness of fit between the estimates of serum concentration (Cl) provided by equation 1 and the measured serum concentration (Cl) was evaluated by F, the sums of squares of the deviations:
The serum concentration and urinary excretion data for each subject in each of the studies presented here were each evaluated, using the method presented above, separately. This paper reports the mean data by drug and subject groups, but the results reported for the bioavailability analyses are from the individual subject analyses. Cefadroxil, cephalexin, and cephradine are each distinctive chemical entities, and it could not be assumed that their in vivo dispositions were identical.-For that reason it was inappropriate to consistently test statistical hypotheses regarding bioavailability within each study by a single multiway analysis of variance (ANOVA). Such an A N O V A was appropriate when testing "treatment" affects on bioavailability for a given antibiotic
within a single study. Thus, when comparing cefadroxil monohydrate and trihydrate in study HL-74-41 and the effect of food and fasting on cefadroxit monohydrate or cephalexin monohydrate in study HL-75-51, such an A N O V A could be used. A two-period crossover design A N O V A (3) served in these cases. When comparing different antibiotics in a single study or performing interstudy comparisons, the more appropriate oneway A N O V A (6) was used. All hypotheses were tested at the P = 0.05 level of significance. Bioavailability comparisons on a given antibiotic were performed using K a, tma x and Cma x to characterize rate of availability and AUC to characterize total extent of availability once statistical equivalence of Kel values in the crossover had been established (10). The urine concentrations of the antibiotics have been calculated and compared at their modes (the concentration values corresponding to the greatest concentration frequencies) rather than their means, since the distributions of urine concentrations were skewed and apparently not normal distributions."
Results and Discussion
Serum concentrations. Tables 1 and 2 , 3 and 4, and 5 and 6 contain the mean serum concentrations and pharmacokinetic parameters + standard error (SE) for studies H L -74-41, HL-75-47, and HL-75-51, respectively. U p to concentrations of 25 ~g/ml, the serum protein bindings of cefadroxil and cephalexin were very similar: cefadroxil was 20% bound, and cephalexin was 17% b o u n d (1). The m o n o h y d r a t e and trihydrate of cefadroxil are fully equivalent to each other. Statistical analyses indicated no significant differences between their rate or total extent of bioavailability. The data from all three studies indicate that cephalexin is more rapidly absorbed than cefadroxil: K a for cephalexin was always greater than Ka for cefadroxil. This led to the later tma x for cefadroxil than for cephalexin. This later tma x for cefadroxil was not due to delayed absorption of the drug; the overall absorption lag times for the two drugs were almost identical at 24 rain for cefadroxil and 20 min for cephalexin. At doses of 500 mg, the m e a n Cma x for cefadroxil (16 Ixg/ml) was about 80% of that for cephalexin (21 Ixg/ml). The overall mean half-life of cefadroxil (1.2 h) was twofold greater than the overall mean half-life of cephalexin (0.6 hi; the A U C for cefadroxil (47.4 ~tgh/ ml) was 1.6-fold greater than the A U C for cephalexin (29.0 Ixgh/ml), indicating that although the peak serum level of cefadroxil is lower than that of cephalexin, cefadroxil persists in the body an appreciably longer time than does cephalexin. At equivalent doses the cefadroxil serum level was higher than the cephalexin serum level by 1.5 h after dose and remained consistently higher thereafter. At the 500-mg dose, cephalexin concentration dropped to 1 ixg/ml at about 4 h, and cefadroxil concentration dropped to 1 ~g/ml at about 7 h. Figures 2 and 3 contain plots of A U C and Cma x v e r s u s dose for all three studies. Linear regression analysis of A U C and Cma x versus dose for cefadroxil and cephalexin was performed using individual subject data (each analysis had 42 degrees of freedom). In each case the slope of the curve was significantly greater than zero (P <0.005 for all four analyses) and the y axis intercept was never significantly greater than zero (P >0.4 foF all four analyses). The linearity of these plots indicates essential pharmacokinetic linearity for serum level data for cefadroxil and cephalexin up to a 500-mg oral dose. The linearity of cefadroxil and cephalexin indicates that we can calculate S 562 Infection 8 (1980) Suppl. 5 serum levels for these antibiotics, at any unknown dose over this range, from serum levels at a known dose by multiplying the known serum levels by the ratio of unknown to known dose (7). We can then calculate the mean serum levels and AUC which would be yielded by a 250-rag dose of cefadroxil. A 250-mg dose of cefadroxil would yield a Cmax 80% as great and an AUC 1.6-fold greater than those produced by the 250-mg dose of cephalexin. and 0.8 h in study HL-75-51. These half-lives remain in the range of expectable biological variability. Cephalexin half-lives ranging from 0.6 to 1.2 h have been reported in the literature (8) . In this series of three studies, cefadroxil consistently had a longer half-life than cephalexin in each of the 44 subjects. We might expect to continue to see consistently longer half-lives for cefadroxil than for cephalexin in humans. Cephalexin is normally administered every 6 h. At approximately 45 min after dosing, a 250-mg dose of cephalexin yields a mean Cm~ of 10 ~g/ml, and at a 500-mg dose it yields a mean Cm,~ of 20 ~g/ml. By 6 h, at 250 mg, there is no detectable cephalexin present in serum. At a 500-mg dose, the mean 6-h serum level is 0.13 ~g/ml. Cefadroxil is more persistent. At a dose of 250 mg it will achieve a mean peak serum level of 8 ~g/ml at approximately 70 min and the mean serum concentration will be 0.33 ~g/ml at 8 h and 0.06 ~g/ml at t2 h. At a dose of 500 mg, cefadroxil has a mean peak serum level of 16 ~g/ml at approximately 70 min and the mean serum concentrations will be 0.65 ~g/ ml at 8 h and 0.11 ~g/ml at 12 h. Cefadroxil would have analogous persistence in urine at these doses. It would seem reasonable to develop clinical efficacy data which, supported by these pharmacokinetic properties, could indicate a 12-h dosing interval for cefadroxil. The disposition of cephradine seems very similar to that of cephalexin. Their serum level curves and the values for their pharmacokinetic parameters are very similar (see Tables 3 and 4) . Concurrent ingestion of food with either cefadroxil or cephalexin on study day 1 (study HL-75-51, Tables 5 and  6 ) had no statistically significant effect on their bioavailability relative to fasting conditions. Neither rates of availability nor total availability were affected. Continued concurrent administration of food did not markedly affect cefadroxil or cephalexin bioavailability. Urinary excretion. Plotting AMu/At versus serum concentrations for cefadroxil and cephalexin gave the results shown in Fig. 4 . These data came from all three studies. Cephradine was excluded for lack of sufficient data. Linear regression analysis indicated that the apparent straight-line portions of these plots were significantly linear. These results enable assignment of specific renal excretion phenomena to glomerular filtration and tubular secretion. Net renal excretion of antibiotic can be represented as renal excretion rate = glomerular filtration rate + tubular secretion rate, i. e.:
dMu/dt = VKuC + TmC/(K m + C)
AMu/At is the numerical approximation to dMu/dt; V is the apparent volume of distribution of drug in the body; Ku is the net first order rate constant for glomerular filtration; C is the serum concentration of drug: T m is the maximum transport rate for tubular secretion, and K mist the Michaelis constant. The term TmC/(K m + C) describes the capacity-limited process and is exactly analogous to the Michaelis-Menten equation for enzyme activity. When C ~K m this reduces to T m and equation 5 becomes:
Equation 9 i s the best overall description of the curves seen in Fig. 4 . At relatively low serum concentrations, less than 0.3 I~g/ml for cephalexin and at about I t~g/ml for cefadroxil, the tubular secretion mechanism has become saturated (i. e., C ~> Kin) and tubular secretion proceeds at its maximum rate, Tm. This constant rate is about 30 mg/h for cephalexin and 15 mg/h for cefadroxil. It appears that cephalexin has a greater affinity for the tubular secretion mechanism than does cefadroxil; cephalexin has a higher T m and a smaller K m. This is the primary reason for the shorter half-life of cephalexin -it is more readily excreted in the urine. The slopes of the linear portions of the plots in Fig. 4 are equivalent to the term VKm, which is the renal clearance rate due to glomerular filtration. This rate is 112 ml/min for cephalexin and 90.1 ml/min for cefadroxil. These rates are statistically equivalent to the commonly accepted value for creatinine clearance rate (gomerular filtration rate) in humans, 95.5 ml/min (2).
Human renal excretion of these tWO cephalosporin antibiotics does not proceed by a completely linear, firstorder process. As cefadroxil or cephalexin dose increases, it would take a longer time to excrete any given percentage of the dose. Since the tubular secretion rate for cefadroxil is less than the tubular secretion rate for cephalexin, the urinary excretion of cefadroxil is of longer duration. Cefadroxil yields initially lower urine concentrations than an equal dose of cephalexin, but cefadroxil maintains higher urine concentrations at the later times (see Tables 7 and 8 ). Within each given experiment the ranges and means of urine volumes remain reasonably constant. The 0-to 3-or 0-to 4-h modal urine concentrations of cefadroxil are lower than the 0-to 3-or 0-to 4-h modal urine concentrations of cephalexin or cephradine. At the 4-to 8-and 3-to 6-or 6-to 12-h intervals, cefadroxil maintains the highest modal urine levels. In study HL-75-47, urine concentrations of cefadroxil were maintained at a relatively constant modal level through 0 to 3 and 3 to 6 h and remained at least twice as high as cephalexin and cephradine modal concentrations from 3 through 12 h. Figure 5 contains cumulative urinary excretion plots drawn from the three studies being reported here. The total cumulative urinary excretion of active cefadroxil and cephalexin are statistically equivalent with an overall mean of approximately 88% of dose. They are almost completely absorbed: there may be small components of their elimination by biliary excretion or metabolism. All of a dose of cephradine appears to be excreted in the urine; presumably, cephradine is completely absorbed and eliminated completely by renal excretion. The total assayed cumulative urinary excretion of antibiotic in some subjects was greater than 100% of the dose, but the range of these recoveries did not exceed the 10 to 15% variability normally expected from cup-plate assays.
Since cefadroxil is eliminated more slowly than cephalexin or cephradine, it has a longer residence time in the body, time in which it could distribute more extensively. The range of the apparent volumes of distribution can be estimated from the relationship, creatinine clearance rate = G.F.R. = VKu. Elimination rate constants may be described as Kel = K u + Knr where K,r is a first-order rate constant for drug elimination via nonrenal routes.
If renal excretion is the only elimination route, then Knr = 0 and K u = K~. This presumes that the active antibiotic excreted in urine represents all of the drug absorbed. If the drug was completely bioavailabte, then the difference between the total dose and the cumulative fraction excreted in the urine (Fe) represents the amount eliminated by nonrenal routes and: Ku = Kel-Knr = FeKel (lo)
since Knr = (1 -Fe)Ket. Thus, the value of K u must lie between Kel and F~K¢~. Applying these limits to the relationship V = G.F.R./K~ we can calculate that the possible range of apparent volumes of distribution for cefadroxil is 9.7 to 11.6 liters (i. e., 14 to 17% of body weight) and for cephalexin it is 5.2 to 5.8 liters (i. e., 7.4 to 8.3% of body weight). The longer duration and more extensive distribution of cefadroxil in vivo are interrelated factors.
